Class 2 Device Recall ARCHITECT Free T3 Reagent Kit

• Date Initiated by Firm: October 12, 2018
• Create Date: February 04, 2019
• Recall Status: Terminated on December 14, 2020
• Recall Number: Z-0798-2019
• Recall Event ID: 81402
• Product Classification: Radioimmunoassay, total triiodothyronine - Product Code CDP
• Product: ARCHITECT Free T3 Reagent Kit used on ARCHITECT i1000SR or i2000/i2000SR platforms; ; Product Usage:; It is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of free triiodothyronine (Free T3) in human serum and plasma.
• Code Information: List number (Kit Configuration): 7K63-20 (4 x 100 tests/kit), 7K63 25 (1 x 100 tests/kit), 7K63 27 (1 x 100 tests/kit), 7K63 30 (4 x 500 tests/kit), 7K63 35 (1 x 500 tests/kit), 7K63 32 (4 x 500 tests/kit), 7K63 37 (1 x 500 tests/kit). All lot codes for each of these list numbers are included in the recall.
• Recalling Firm/ Manufacturer: Abbott Ireland Diagnostics Division; Lisnamuck; Co. Longford Ireland
• For Additional Information Contact: 877-4222688
• Manufacturer Reason for Recall: Samples tested using ARCHITECT Free T3 or ARCHITECT Total T3 assays may show depressed results due to a reagent carryover when testing on board with specific assays on the ARCHITECT i1000SR and i2000/i2999SR platforms.
• FDA Determined Cause: Device Design
• Action: Abbott notified customers on about 10/12/218 via "Product Correction Urgent - Immediate Action Required" letter. Letters were sent separately to customers who utilize the ARCHITECH i1000SR platform and the i2000/i2000SR platforms. Necessary actions for customers who utilize the ARCHITECH i1000SR platform included that if a separate instrument can be used, then separate the ARCHITECT Free T3 and ARCHITECT Total T3 assays from the specific assays listed in the letter (ARCHITECT TSH, ARCHITECT TUptake, ARCHITECT HIV Ag/Ab Combo, ARCHITECT Cortisol, ARCHITECT LH, ARCHITECT ProGRP, ARCHITECT rHTLVI/II, ARCHITECT Total PSA, ARCHITECT AFP, ARCHITECT Free PSA, ARCHITECT 25OH Vitamin D), by running these tests on different instruments. For those customers who cannot use a separate instrument, then they are instructed to perform the Maintenance Procedure (6445 Pipettor/WZ Probe Cleaning for i1000SR) in the i1000SR Operations on the instrument prior to performing batch testing for all ARCHITECT Free T3 or ARCHITECT Total T3 samples. Necessary actions for customers who utilize the i2000/i2000SR platforms included that if a separate instrument can be used, then separate the ARCHITECT Free T3 and ARCHITECT Total T3 assays from the ARCHITECT 25OH Vitamin D assay, by running these tests on different instruments. For those customers who cannot use a separate instrument, then perform Daily Maintenance (Operations Manual, 6041 for i2000/i2000SR) on the instrument prior to performing batch testing for all ARCHITECT Free T3 or ARCHITECT Total T3 samples. Additionally, instructions for both types of affected platforms included to review the letter with each customer site's Medical Director or Laboratory Director and follow laboratory protocol regarding the need for reviewing previously reported patient results. If the product has been forwarded to other laboratories, please inform them of the recall and provide a copy of the notification letter. Also, complete and r
• Quantity in Commerce: 191,410 units total
• Distribution: Worldwide Distribution - US Nationwide distribution to AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NJ, NV, NY, OH, OK, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WV, WY, PR. International distribution to AFGHANISTAN, ALBANIA, ALGERIA, ANGOLA, ARMENIA, AUSTRIA, AZERBAIJAN, BAHAMAS, BAHRAIN, BANGLADESH, BELARUS, BELGIUM, BOSNIA AND HERZEGOVI, BRUNEI, BULGARIA, BURKINA FASO, CAMEROON, CANADA, CAYMAN ISLANDS, CHILE, CROATIA, CYPRUS, CZECH REPUBLIC, DEM. REP. OF THE CON, DENMARK, ECUADOR, EGYPT, EL SALVADOR, ESTONIA, ETHIOPIA, FINLAND, FRANCE, GAZA & JERICHO, GEORGIA, GERMANY, GHANA, GREECE, HONDURAS, HUNGARY, INDONESIA, IRAN, IRAQ, IRELAND, ISRAEL, ITALY, IVORY COAST, JAMAICA, JORDAN, KAZAKHSTAN, KENYA, KUWAIT, KYRGYZSTAN, LATVIA, LEBANON, LIBYA, LITHUANIA, LUXEMBOURG, MACEDONIA, MALAWI, MALAYSIA, MALDIVES, MALI, MAURITANIA, MAURITIUS, MOLDOVA, MONTENEGRO, MOROCCO, MOZAMBIQUE, NEPAL, NETHERLANDS, NICARAGUA, NIGERIA, NORWAY, OMAN, PAKISTAN, PANAMA, PARAGUAY, PERU, POLAND, PORTUGAL, QATAR, REPUBLIC OF YEMEN, ROMANIA, RUSSIA, RWANDA, SAUDI ARABIA, SENEGAL, SERBIA, SINGAPORE, SLOVAKIA,SLOVENIA, SOUTH AFRICA, SPAIN, SRI LANKA, ST. LUCIA, ST. VINCENT, SWEDEN, SWITZERLAND, TANZANIA, THE GAMBIA,TRINIDAD & TOBAGO, TUNISIA, TURKEY, UAE, UGANDA, UKRAINE,UNITED KINGDOM, VIETNAM, ZIMBABWE.
• Total Product Life Cycle: TPLC Device Report

¹ A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
² Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
³ For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.